Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- Iveric's positive top-line data for macular degeneration brings its stock into focuson October 28, 2019 at 5:39 pm
Upbeat top-line data for New York-based Iveric Bio Inc.'s phase IIb trial testing Zimura in dry age-related macular degeneration propelled the company stock (NASDAQ:ISEE) 82.8% upward in Monday's ...
- Age-Related Macular Degeneration Market visualized increasing with 7.8 % CAGR and reach around USD 11,186.8 Million between 2019 and 2023on October 28, 2019 at 2:25 am
The Age-Related Macular Degeneration Market report summarizes emerging key players in the market along with effective strategies followed by them. The report gives new and innovative ideas to provide ...
- Study pinpoints cell types linked to age-related macular degenerationon October 25, 2019 at 6:39 am
Age-related macular degeneration is one of the leading causes of blindness in the elderly, affecting more than 2 million people in the United States and leading to progressive loss of central vision.
- Association of Vision-related Quality of Life with Visual Function in Age-Related Macular Degenerationon October 25, 2019 at 2:22 am
The purpose of this study was to assess which visual function measures are most strongly associated with vision-related quality of life (VRQoL) in age-related macular degeneration (AMD). A ...
- Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degenerationon October 25, 2019 at 2:17 am
Genome-wide association studies (GWAS) have identified genetic variants associated with age-related macular degeneration (AMD), one of the leading causes of blindness in the elderly. However, it has ...
via Google News and Bing News